Is ICON (NasdaqGS:ICLR) Offering An Opportunity After Recent Share Price Volatility?
- If you're wondering whether ICON's recent share price levels reflect a fair deal or an opportunity, this article walks through what the current market price might be indicating about value.
- The stock closed at US$106.81, with returns of 8.6% over 30 days, while year-to-date and 1-year returns of 43.4% and 25.8% declines show a very different picture for longer-term holders.
- Recent coverage around ICON has focused on broad sector sentiment and how contract research organizations fit into healthcare spending priorities. This helps frame why investors are reassessing risk and reward. This backdrop is important context when thinking about whether current pricing reflects caution, renewed interest, or simply volatility.
- ICON currently has a valuation score of 5 out of 6. The rest of this article walks through the key valuation approaches behind that score before touching on a more complete way to think about what the stock could be worth.
Find out why ICON's -25.8% return over the last year is lagging behind its peers.
Approach 1: ICON Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes the cash ICON is expected to generate in the future and discounts those projections back to today to estimate what the business could be worth right now in dollar terms.
ICON is currently generating last twelve months free cash flow of about $980.9 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates project free cash flow out to 2035, with 2030 free cash flow projected at $1,176.45 million. Simply Wall St uses analyst inputs through 2029, then extends the trend for the later years.
When all these projected cash flows are discounted back and combined, the model arrives at an estimated intrinsic value of about $222.42 per share. Compared with the recent share price of $106.81, the DCF output suggests ICON trades at a 52.0% discount.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 52.0%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.
Approach 2: ICON Price vs Earnings
For a profitable company like ICON, the P/E ratio is a straightforward way to gauge how much you are paying for each dollar of earnings. It gives a quick snapshot of what the market is willing to pay for the business today, relative to its current profit.
What counts as a "normal" or "fair" P/E depends heavily on expectations for future earnings and the level of risk. Higher growth and lower perceived risk usually justify a higher P/E, while slower growth or higher risk tend to line up with a lower multiple.
ICON currently trades on a P/E of 13.61x. That sits below the Life Sciences industry average P/E of 33.89x and below the peer group average of 44.72x. On simple comparisons alone, this might look conservative. To go a step further, Simply Wall St calculates a Fair Ratio of 18.44x, a proprietary P/E level that reflects ICON's earnings growth profile, industry, profit margins, market cap and risk characteristics.
This Fair Ratio is more tailored than a basic peer or industry comparison because it aims to match the multiple to ICON's own fundamentals, not just its sector label. Comparing the Fair Ratio of 18.44x with the actual P/E of 13.61x suggests the shares may be trading below that modelled level.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your ICON Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple way to turn your view of ICON into a story that links your assumptions about future revenue, earnings and margins to a forecast and then to a Fair Value you can compare with the current share price.
On Simply Wall St's Community page, Narratives sit on top of the numbers. You can see, for example, a cautious ICON view that ties a Fair Value of US$75.00 to expectations for flatter revenue and tighter margins. You can also see a more optimistic view that connects a Fair Value of about US$226.60 to higher revenue and margin assumptions. All of this updates automatically as new news or earnings arrive.
For ICON however, we will make it really easy for you with previews of two leading ICON Narratives:
Fair value: US$142.86
Implied pricing: about 25.2% below this fair value at the recent US$106.81 share price
Revenue growth assumption: 2.30% a year
- Analysts in this camp see accounting-related uncertainty and the recent selloff as already reflected in current pricing, with oncology expansion and midsized pharma partnerships helping sentiment reset over time.
- Their assumptions include revenue rising to US$8.8b, earnings of US$1.0b and a P/E of 17.6x by 2028, using an 8.3% discount rate and expecting fewer shares on issue as buybacks continue.
- Key watchpoints are clinical trial cancellations, pricing pressure from other contract research organizations, and any impact from an internal accounting investigation on reported earnings and backlog.
Fair value: US$75.00
Implied pricing: about 42.4% above this fair value at the recent US$106.81 share price
Revenue growth assumption: 0.57% a year
- This group of analysts focuses on the accounting review, backlog uncertainty and trial cancellations, arguing that these issues could weigh on earnings quality and keep pressure on sentiment.
- Their model leans on flatter revenue at about US$8.2b, earnings of US$497.1m and a P/E of 13.4x by 2029, using a 9.5% discount rate and still building in share count reduction over time.
- Risks that could soften this view include stronger demand for clinical trials, deeper pharma partnerships and effective use of AI and automation, all of which could support margins and earnings more than this bear case allows for.
Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com